Acquisition by Paulson Richard A. of 24900 shares of Bluebird Bio subject to Rule 16b-3

BLUE Stock  USD 0.38  0.01  2.56%   
About 67% of Bluebird Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Bluebird bio suggests that many traders are alarmed. The current market sentiment, together with Bluebird Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Bluebird bio stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Bluebird bio Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at finance.yahoo.com
Yahoo News
  

Bluebird Bio Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Bluebird Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Bluebird Bio Fundamental Analysis

We analyze Bluebird Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluebird Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluebird Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Bluebird Bio is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Bluebird bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bluebird Bio stock to make a market-neutral strategy. Peer analysis of Bluebird Bio could also be used in its relative valuation, which is a method of valuing Bluebird Bio by comparing valuation metrics with similar companies.

Peers

Bluebird Bio Related Equities

HEPAHepion Pharmaceuticals   5.08   
0%
35.0%
SRPTSarepta Therapeutics   0.73   
5.0%
0%
MDGLMadrigal Pharmaceuticals   1.33   
9.0%
0%
KPTIKaryopharm Therapeutics   1.37   
9.0%
0%
CVACCureVac NV   2.14   
15.0%
0%
YMABY MAbs   2.40   
16.0%
0%
VKTXViking Therapeutics   2.72   
19.0%
0%
TVTXTravere Therapeutics   4.12   
29.0%
0%
PTCTPTC Therapeutics   4.65   
32.0%
0%
VIRVir Biotechnology   4.99   
35.0%
0%
KRYSKrystal Biotech   7.33   
51.0%
0%
ZNTLZentalis Pharmaceuticals   10.57   
74.0%
0%
AGIOAgios Pharm   11.99   
84.0%
0%
MRSNMersana Therapeutics   14.18   
100.0%
0%

Complementary Tools for Bluebird Stock analysis

When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
FinTech Suite
Use AI to screen and filter profitable investment opportunities